J&J wagers $2 billion to acquire Ambrx

8 January 2024

Kicking of the JP Morgan Healthcare conference this morning, Johnson & Johnson (NYSE: JNJ) announced a definitive agreement to acquire Ambrx Biopharma (Nasdaq: AMAM), sending the latter’s shares rocketing more than 97% to $26.92 in early trading.

Ambrx is a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs) and its assets will strengthen J&J’s pipeline in the increasingly attractive sector.

Under the terms of the transaction, J&J will acquire all of the outstanding shares of Ambrx’ common stock for $28.00 per share in cash through a merger of Ambrx with a subsidiary of the company, valuing the La Jolla, California-based company at around $2 billion. The closing of the transaction is expected to occur in the first half of 2024,

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK